Back to News
Market Impact: 0.35
Amgen Announces Positive Topline Phase 3 Results For Dazodalibep In Sjogren's Disease
Source: Nasdaq
Healthcare & BiotechProduct Launches
Amgen reported positive topline results from its Phase 3 OASIZ 301 trial of dazodalibep in adults with Sjogren's disease and moderate-to-severe systemic disease activity. The positive late-stage clinical outcome supports the drug's development and could strengthen Amgen's inflammatory-disease pipeline, though no efficacy or safety figures were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
AMGN0.78
More News
- While biotech bets swing on trial data, this dividend payer gained 72% since 2024
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Musk says Tesla to wind down polarising Cybertruck production as sales lag
- Tesla to wind down Cybertruck production at Texas factory next year to make room for Cybercab
- Ferrari’s Luce was ridiculed as a ‘Magic Mouse on wheels.’ Now the EV is sold out for 2027, and buyers haven’t even driven it yet
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO